WO2004113921A9 - Reactif pour analyse de l'anticorps anti- treponema pallidium et methode d'analyse de cet anticorps - Google Patents

Reactif pour analyse de l'anticorps anti- treponema pallidium et methode d'analyse de cet anticorps

Info

Publication number
WO2004113921A9
WO2004113921A9 PCT/JP2004/008902 JP2004008902W WO2004113921A9 WO 2004113921 A9 WO2004113921 A9 WO 2004113921A9 JP 2004008902 W JP2004008902 W JP 2004008902W WO 2004113921 A9 WO2004113921 A9 WO 2004113921A9
Authority
WO
WIPO (PCT)
Prior art keywords
treponema pallidum
antigen
antibody
kda
molecular weight
Prior art date
Application number
PCT/JP2004/008902
Other languages
English (en)
Japanese (ja)
Other versions
WO2004113921A1 (fr
Inventor
Mie Matsumoto
Yoshitaka Izumoto
Original Assignee
Sekisui Chemical Co Ltd
Mie Matsumoto
Yoshitaka Izumoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2003180087A external-priority patent/JP3936678B2/ja
Application filed by Sekisui Chemical Co Ltd, Mie Matsumoto, Yoshitaka Izumoto filed Critical Sekisui Chemical Co Ltd
Publication of WO2004113921A1 publication Critical patent/WO2004113921A1/fr
Publication of WO2004113921A9 publication Critical patent/WO2004113921A9/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/571—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses for venereal disease, e.g. syphilis, gonorrhoea
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Definitions

  • the present invention relates to an anti-treponema pallidum antibody measuring reagent capable of measuring an anti-treponema pallidum antibody with high sensitivity and specificity, and a measuring method using the same.
  • Syphilis is a disease caused by infection of Treponema pallidum (Treponema pallidum). Syphilis is diagnosed by detecting the presence of anti-syphilis anti-syphilis antibodies in blood by immunoassay. Many surface antigens are present on the surface of Treponema pallidum, and immunoassays are performed by a method utilizing an antigen-antibody reaction between the surface antigen and an anti-Treponemal syphilis antibody in a specimen.
  • Non-Patent Document 1 Among the major surface antigens present on the cell surface of Treponema pallidum, those with a molecular weight of 47 kDa, 42 kDa, 37 kDa, 17 kDa and 15 kDa are known (Non-Patent Document 1).
  • Treponema pallidum As the surface antigen of Treponema pallidum which is currently used in this immunoassay, Treponema pallidum is cultivated in a house testicle, solubilized with a surfactant or the like, and extracted by various methods. Unnecessary substances are removed by use. Purified necessary components are used. However, the production method using such a rabbit is limited in yield due to the use of animals as a host, and the growth state of Treponema pallidum varies among animals. There was a problem that it was difficult to secure them. At the moment, on the other hand, we have succeeded in directly cultivating Treponema syphilis directly.
  • Patent Document 1 describes a method for preparing an antigen having a molecular weight of 47 kDa of Treponema pallidum by genetic engineering and immunoassaying an anti-Treponemal antibody using the antigen.
  • Patent Document 2 discloses that daltathio is added to the N-terminus of 15 kDa and 17 kDa surface antigens. A method using a protein fused with N-S-transferase has been disclosed! / In addition, other methods have been reported for the measurement of anti-Treponemal antibody against syphilis using an antigen having a specific molecular weight prepared by a specific method.
  • Patent Document 1 Japanese Patent Application Laid-Open No. 2-500403
  • Patent Document 2 JP-A-7-287017
  • Non-Patent Document 1 Journal of Immunology, vol. 129, pp. 1287—1291, 1982 Disclosure of Invention
  • an object of the present invention is to provide an anti-treponema pallidum antibody measuring reagent capable of measuring an anti-treponema pallidum antibody with high sensitivity and specificity, and a measuring method using the same. Things.
  • the present invention relates to a reagent used for measuring an anti-Treponemal anti-Syphilis antibody utilizing an antigen-antibody reaction, wherein the 15K antigen comprising a protein in which j3-galactosidase is fused to a surface antigen having a molecular weight of 15 kDa of syphilis and Z or
  • This is an anti-treponema pallidum antibody measurement reagent containing a 17K antigen consisting of a protein in which ⁇ -extragalactosidase is fused to a surface antigen with a molecular weight of 17 kDa.
  • the present inventors have conducted intensive studies and found that among the surface antigens of Treponema pallidum, a 15K antigen and / or a 17kDa surface antigen consisting of a protein in which ⁇ -galactosidase is fused to a surface antigen having a molecular weight of 15 kDa.
  • a 15K antigen and / or a 17kDa surface antigen consisting of a protein in which ⁇ -galactosidase is fused to a surface antigen having a molecular weight of 15 kDa By using the 17K antigen consisting of a protein fused with ⁇ -galactosidase as an antigen, it was found that the anti-Treponemal anti-Syphilis antibody could be measured with significantly higher sensitivity than the conventional method, but with extremely high accuracy.
  • the present invention has been completed.
  • the anti-Treponemal anti-Syphilis antibody measuring reagent of the present invention has a molecular weight of 15 kDa of Treponema pallidum.
  • Corrected form (Rule 91) It contains a 15K antigen consisting of a protein in which ⁇ -galactosidase is fused to the surface antigen and / or a 17 ⁇ antigen consisting of a protein in which ⁇ -galactosidase is fused to the surface antigen of molecular weight 17 kDa of Treponema pallidum.
  • Either one of these antigens may be contained, or both may be contained. In particular, when both are included, it is preferable because the detection sensitivity is further increased.
  • the method for fusing ⁇ -galactosidase to the surface antigen having a molecular weight of 15 kDa and the surface antigen having a molecular weight of 17 kDa of the Treponema pallidum is not particularly limited, and an ordinary method can be used.
  • ⁇ -galactosidase is an enzyme that decomposes and synthesizes ratatose, and has been studied in Escherichia coli as a typical inducible enzyme induced by the force ratatose.
  • ⁇ -galactosidase has a molecular weight of about 116 kDa and forms a tetramer. Its structural gene is called lacZ, and its gene sequence is known (EMBO J 1963; 2 (4): 593-597) and is commercially available in various plasmids. Representative examples of commercially available ones include pUC18 and pUC19 (both manufactured by Toyobo Co., Ltd.), and those that can express a fusion protein of a foreign protein and / 3-galactosidase. It is not particularly limited.
  • the method for fusing ⁇ -galatatosidase to the surface antigen having a molecular weight of 15 kDa and the surface antigen having a molecular weight of 17 kDa of the Treponema pallidum is as follows: Introduce to Such a method can be performed by a gene recombination technique known to those skilled in the art, and is not particularly limited.
  • a method for purifying a fusion protein obtained by fusing -galactosidase with a surface antigen having a molecular weight of 15 kDa or a surface antigen having a molecular weight of 17 kDa of Treponema pallidum is not particularly limited.
  • p-aminobenziru 1_thio j3 _D examples include a method of purifying using an agarose column to which galactopyranoside is bound (for example, manufactured by Sigma) or an anti-j3-galactosidase antibody (for example, manufactured by Promega).
  • proteins obtained by fusing monogalactosidase to the surface antigen having a molecular weight of 15 kDa and the surface antigen having a molecular weight of 17 kDa of the Treponema pallidum are generally sold, and therefore, these commercially available products can also be used.
  • the 15K antigen composed of a protein obtained by fusing / 3-galatatosidase to a surface antigen having a molecular weight of 15 kDa and the 17K antigen composed of a protein obtained by fusing a ⁇ -galactosidase to a surface antigen having a molecular weight of 17 kDa is obtained from It may be immobilized on a suitable carrier such as latex particles. By immobilizing it on a strong carrier, the reagent for measuring an anti-treponema pallidum antibody of the present invention can be subjected to an immunoagglutination method or the like.
  • the method of immobilization is not particularly limited, and examples thereof include a physical adsorption method and a method of chemically bonding to a functional group provided on the surface of the carrier.
  • Both the 15K antigen consisting of a protein in which ⁇ -galactosidase is fused to a surface antigen having a molecular weight of 15 kDa and the 17K antigen consisting of a protein in which a galactosidase is fused to a surface antigen having a molecular weight of 17 kDa are known.
  • these are used for immunoassay of anti-Treponemal syphilis antibodies their sensitivity is dramatically improved as compared with the case where a surface antigen not fused to ⁇ -galatatosidase is used, and In addition, a decrease in detection accuracy due to a non-specific reaction can be suppressed.
  • a method for measuring an anti-treponema pallidum antibody in a sample using an antigen-antibody reaction wherein the antigen is a 15K antigen consisting of a protein in which / 3_galactosidase is fused to a surface antigen having a molecular weight of 15 kDa of trepidome syphilis, and 15K antigen and Z or syphilis.
  • a method for measuring an anti-treponema pallidum antibody using a 17K antigen consisting of a protein obtained by fusing / 3_galactosidase to a surface antigen having a molecular weight of 17 kDa of treponemal is also one of the present invention.
  • the method for measuring the anti-treponema pallidum antibody of the present invention is not particularly limited as long as the reagent for measuring the anti-treponema pallidum antibody of the present invention is used, and can be performed by a usual method. That is, if classified according to the reaction format, the sandwich method, agglutination method, etc. can be used.If classified according to the label, the enzyme immunoassay, fluorescence analysis, radioimmunoassay, etc. can be used. . Among them, the latex immunoagglutination method, which is easy to operate, has good sensitivity, and is suitable for processing a large number of samples, is more preferable.
  • Specific examples of the method for measuring an anti-treponema pallidum antibody of the present invention include, for example, a 15K antigen comprising a protein in which ⁇ -galatatosidase is fused to a surface antigen having a molecular weight of 15 kDa and / or the molecular weight of treponema pallidum.
  • a 17K antigen consisting of a 17-kDa surface antigen fused with / 3-galatatosidase is immobilized on latex particles, prepared as a latex reagent by a specified procedure, and a sample is added to it for reaction for a specified time.
  • a method of visually, optically, or electrochemically detecting a change in turbidity at intervals may be used.
  • a 15K antigen comprising a protein obtained by fusing ⁇ -galactosidase to a surface antigen having a molecular weight of 15 kDa on a well of a microtiter plate or the like and a molecular weight of 15 kDa and / or the molecular weight of A 17kDa surface antigen is immobilized with a 17K antigen consisting of a protein fused with -galatasidase, blocking nonspecific adsorption sites, washing, adding a sample to react, washing, and enzyme such as peroxidase. Reacting with an anti-human immunoglobulin antibody labeled with, washing, adding the substrate of the labeled antibody, performing an enzymatic reaction, causing color development, and measuring the degree of color development after termination of the reaction by absorbance measurement.
  • a 17K antigen comprising a protein obtained by fusing ⁇ -galactosidase to a surface antigen having a molecular weight of 15
  • a 15K antigen consisting of a protein in which ⁇ -galactosidase is fused to a surface antigen having a molecular weight of 15 kDa of syphilis treponema on particles such as ferrite magnetic particles, and / or a molecular weight of 17 kDa of syphilis treponema
  • a 17K antigen consisting of a protein fused with 3 / 3-galactosidase is immobilized on the surface antigen of, and a sample is added to react with the antigen.
  • an anti-human immunoglobulin antibody labeled with an enzyme such as peroxidase and a chemiluminescent substrate are used.
  • a chemiluminescent enzyme immunoassay (CLEIA).
  • a solubilized carrier for example, an artificial carrier composed of gelatin or the like disclosed in JP-B-63-29223; immobilized on a particle carrier such as animal erythrocytes such as chickens, goats, sheep, poma, and porch;
  • agglutination immunoassay method in which a sample is collected in a suspension of a carrier and the force of agglutination of the particles is measured.
  • the sample to be used in the method for measuring an anti-treponema pallidum antibody of the present invention is not particularly limited, and examples thereof include a body fluid such as serum of a human animal to be diagnosed with syphilis and a dilution thereof.
  • the method for measuring an anti-treponema pallidum antibody of the present invention can measure an anti-treponema pallidum antibody with extremely high sensitivity and accuracy by using the reagent for measuring an anti-treponema pallidum antibody of the present invention. Diagnosis of syphilis can be made.
  • an anti-treponema pallidum antibody measuring reagent capable of measuring an anti-treponema pallidum antibody with high sensitivity and specificity, and a measuring method using the same can be provided.
  • Latex solution (manufactured by Sekisui Chemical Co., Ltd .: average particle size: 0.3 ⁇ , solid content: 10%) While stirring 0.05 mL in a test tube, fructose-tidase is fused to the surface antigen of Treponema pallidum having a molecular weight of 15 kDa. LmL of the resulting protein solution (Bios Pacific, 100 ⁇ g / mL) was added to immobilize the fusion protein on the surface of the latex particles.
  • the antigen-unadsorbed portion of the obtained fusion protein-immobilized latex particles is blocked with a PBS buffer containing 1% bovine serum albumin (BSA), and the unadsorbed antigen is centrifuged. After removal by washing and sufficient stirring, the mixture was diluted to 0.1% with a PBS buffer containing 1% BSA to obtain an anti-Treponemal antibody measurement reagent.
  • BSA bovine serum albumin
  • Example 2 Instead of a protein solution obtained by fusing ⁇ -galactosidase to a surface antigen having a molecular weight of 15 kDa with Treponema pallidum, a protein solution obtained by fusing -galatatosidase to a surface antigen having a molecular weight of 17 kDa with Treponema pallidum (Bios Pacific, 100 ⁇ g / mL) was used in the same manner as in Example 1 to prepare a reagent for measuring an anti-Treponemal antibody.
  • a 15 kDa surface antigen solution (GST15 antigen, Biokit, 100 x gZmL) of T. syphilis was used instead of a protein solution obtained by fusing ⁇ -galatatosidase to a surface antigen of 15 kDa molecular weight of Treponema pallidum. Except for the above, an anti-syphilis treponemal antibody measurement reagent was prepared in the same manner as in Example 1.
  • a surface antigen solution of 17 kDa molecular weight of Treponema pallidum (GST17 antigen, Biokit, 100 ⁇ g / mL) was used instead. Except for using, a reagent for measuring anti-Syphilis treponemal antibody was prepared in the same manner as in Example 2.
  • a fully automatic analyzer (Hitachi, Model 7170) was used to determine syphilis as a syphilis positive serum from clinical symptoms. Serum was diagnosed as syphilis-negative serum, and 20 cases of non-syphilis normal human serum were tested as samples.
  • a sample dilution buffer PBS buffer containing 1% BSA
  • Table 1 Furthermore, based on the data shown in Table 1, the reaction amount is shown on the vertical axis, and the reaction amount is shown in FIG. 1 for syphilis-positive serum and in FIG. [0032] Table 1 shows that when the anti-treponema pallidum antibody assay reagents prepared in Examples 1 and 2 using a fusion protein fused with galactosidase were used, Comparative Example 1 using an antigen not fused with ⁇ -galactosidase was used. It was found that sera from syphilis patients could be detected with higher sensitivity and that non-specific reactions in the syphilis-negative serum group were lower than those using the prepared anti-treponema pallidum antibody assay reagent.
  • an anti-treponema pallidum antibody measuring reagent capable of measuring an anti-treponema pallidum antibody with high sensitivity and specificity, and a measuring method using the same.
  • FIG. 1 shows the results of an anti-treponema syphilis antibody assay performed on syphilis-positive sera in Examples.
  • FIG. 2 is a graph showing the results of an anti-treponema antibody assay for syphilis performed in Examples.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un réactif permettant d'analyser l'anti-corps anti-Treponema pallidum spécifiquement et avec une grande sensibilité ainsi qu'une méthode d'analyse correspondante. Plus précisément, l'invention concerne un réactif utilisé pour analyser l'anti-corps anti-Treponema pallidum au moyen d'une réaction antigène-anticorps, c'est-à-dire un réactif permettant d'analyser un anti-corps anti-Treponema pallidum qui contient un antigène 15K comprenant une protéine dont la β-galactosidase est fusionnée avec un antigène de surface (poids moléculaire: 15kDa) de Treponema pallidum et/ou un antigène 17k comprenant une protéine dont la β-galactosidase est fusionnée avec un antigène de surface (poids moléculaire: 17 kDa) de Treponema pallidum.
PCT/JP2004/008902 2003-06-24 2004-06-24 Reactif pour analyse de l'anticorps anti- treponema pallidium et methode d'analyse de cet anticorps WO2004113921A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003-180087 2003-06-24
JP2003180087A JP3936678B2 (ja) 2002-07-19 2003-06-24 抗梅毒トレポネーマ抗体測定試薬及び抗梅毒トレポネーマ抗体の測定方法

Publications (2)

Publication Number Publication Date
WO2004113921A1 WO2004113921A1 (fr) 2004-12-29
WO2004113921A9 true WO2004113921A9 (fr) 2005-07-14

Family

ID=33535114

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/008902 WO2004113921A1 (fr) 2003-06-24 2004-06-24 Reactif pour analyse de l'anticorps anti- treponema pallidium et methode d'analyse de cet anticorps

Country Status (1)

Country Link
WO (1) WO2004113921A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104698185B (zh) * 2015-02-10 2016-08-31 深圳市新产业生物医学工程股份有限公司 检测梅毒螺旋体抗体的试剂盒及其检测方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3216473B2 (ja) * 1994-02-28 2001-10-09 富士レビオ株式会社 抗梅毒トレポネマ抗体の測定方法
JP3831759B2 (ja) * 1995-12-20 2006-10-11 富士レビオ株式会社 抗梅毒トレポネーマ抗体の免疫分析方法及び免疫分析装置
JP4318092B2 (ja) * 2000-12-28 2009-08-19 株式会社シノテスト 測定対象物質の測定試薬及び測定対象物質の測定試薬の安定化方法
JP3799410B2 (ja) * 2002-05-20 2006-07-19 株式会社シノテスト 非特異反応抑制ペプチド、並びにこれを用いた非特異反応抑制方法及び抗体測定方法

Also Published As

Publication number Publication date
WO2004113921A1 (fr) 2004-12-29

Similar Documents

Publication Publication Date Title
JP3542808B2 (ja) 細胞計数イムノアッセイ
JP2001505663A (ja) 抗原特異的ＩｇＧ検出
JP2636331B2 (ja) 抗原特異的な抗体の一段階測定法およびそれに適する試薬
CA1180274A (fr) Dosage immunologique des proteines
JP4426103B2 (ja) 生物流体中のβ−ラクタム環を含む抗生物質を測定するための方法
CN110806487A (zh) 一种用于人肝素结合蛋白检测的试剂盒及其制备方法
JP5647599B2 (ja) 生物学的試料中の物質を検出する方法
WO2001032908A1 (fr) Anticorps monoclonal, hybridome, immunoessai et necessaire a diagnostic
JP2007510165A (ja) 結合アッセイ成分
JPWO2002048711A1 (ja) 免疫学的分析試薬及び分析方法
EP0670494A2 (fr) Essai immunologique d'anticorps anti-tréponèmes
JPH02253162A (ja) 特異的結合能を有する物質と結合したエクオリンを用いる検出法
CA1117414A (fr) Dosage immunochimique de la ldh.sub.1
WO2004113921A9 (fr) Reactif pour analyse de l'anticorps anti- treponema pallidium et methode d'analyse de cet anticorps
JP3337575B2 (ja) 抗ストレプトリジンｏ抗体の決定方法
JP3936678B2 (ja) 抗梅毒トレポネーマ抗体測定試薬及び抗梅毒トレポネーマ抗体の測定方法
JP3799410B2 (ja) 非特異反応抑制ペプチド、並びにこれを用いた非特異反応抑制方法及び抗体測定方法
WO2021187406A1 (fr) Anticorps pour la détection d'helicobacter pylori
JP3216473B2 (ja) 抗梅毒トレポネマ抗体の測定方法
EP0485377A1 (fr) Immuno-analyse en phase solide avec conjugue marque
JP2651438B2 (ja) 酵素標識抗体感作ラテックス及びそれを用いた酵素免疫測定法
JP4491572B2 (ja) 酵素免疫測定法による試料中の測定対象物質の測定試薬及び測定方法
WO2004048976A1 (fr) Procede d'analyse du staphylococcus aureus
JP3715736B2 (ja) 抗トレポネーマ抗体測定試薬の製造方法及び抗トレポネーマ抗体測定試薬
JP3938627B2 (ja) リジン親和性物質の測定方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGE 2, DESCRIPTION, REPLACED BY A NEW PAGE 2; AFTER RECTIFICATION OF OBVIOUS ERRORS AUTHORIZED BY THE INTERNATIONAL SEARCH AUTHORITY

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase